Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Zusätzlich bieten wir Ihnen IDH1 Antikörper (210) und IDH1 Proteine (16) und viele weitere Produktgruppen zu diesem Protein an.
Showing 7 out of 24 products:
Human IDH1 ELISA Kit für Sandwich ELISA - ABIN423443
Tan, Jiang, Sun, Chen, Lv, Shao, Li, Qiu, Gao, Li, Tan, Zhou, Wang, Ding, Wang, Sun, Hang, Shi, Feng, He, He: Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. in Molecular & cellular proteomics : MCP 2012
Show all 3 Pubmed References
IDH1/2 mutations induce a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase inhibitors
To confirm this result, we analyzed survival data from 142 LGGs from TCGA with IDH1/IDH2 (zeige IDH2 ELISA Kits) mutations and no 1p19q codeletion. Despite the high rate of censured data, we found that CNLOH 17p, including the TP53 (zeige TP53 ELISA Kits) locus, was associated with better outcome (OR = 0.27; p = .026)
Results suggest that to better treat gliomas, isocitrate dehydrogenase (NADP(+)) 1 (IDH-1) mutation status should be included when determining WHO2007 grade in glioma patients.
The found of this study suggest that IDH1 mutation status had greater impact than histological and other genomic features on miRNA expression patterns.
6 cases of diffuse glioma that presented a diagnostic challenge due to conflicting IDH1/IDH2 (zeige IDH2 ELISA Kits), ATRX (zeige ATRX ELISA Kits), and 1p/19q results.
Study indicates IDH1 mutation status was not predictive of 6-month progression free survival or radiographic response in recurrent glioblastoma trials for this data set.
Study demonstrates that patients with IDH1 mutant tumor have significantly higher brain network global efficiency and degree compared to patients with wild type tumor, despite having larger tumor volumes.
In this review, we focus on three key areas in acute myeloid leukemia (zeige BCL11A ELISA Kits) (AML (zeige RUNX1 ELISA Kits)) developmental therapeutics: FLT3 (zeige FLT3 ELISA Kits) inhibitors, IDH(IDH1 and IDH2 (zeige IDH2 ELISA Kits) ) inhibitors, and drugs that may be particularly beneficial in secondary AML (zeige RUNX1 ELISA Kits)
The role of mutant IDH1 and IDH2 (zeige IDH2 ELISA Kits) inhibitors in the treatment of acute myeloid leukemia (zeige BCL11A ELISA Kits).
Data suggest that identification of IDH1-R132H and ATRX (zeige ATRX ELISA Kits) loss status in the primary-recurrent gliomas may aid in treatment strategy selection, therapeutic trial design, and clinical prognosis evaluation.
IDH1 mutations caused down-regulation of leukocyte chemotaxis, resulting in repression of the tumor-associated immune system.
Idh1(R132H) mutation in the major adult neurogenic stem cell niche causes a phenotype resembling gliomagenesis
Mutant IDH1 downregulates the DNA damage (DD) sensor ATM (zeige ATM ELISA Kits) by altering histone methylation, leading to impaired DNA repair, increased sensitivity to DD, and reduced HSC (zeige FUT1 ELISA Kits) self-renewal, independent of TET2 (zeige TET2 ELISA Kits).
Using whole RNA sequencing of bone marrow cells in iron-overloaded mice, it was observed that Idh1 and Aco1 (zeige ACO1 ELISA Kits), enzymes involved in the TCA cycle, were elevated.
data suggest that mutant IDH1 contributes to malignancy in the T-cell lineage and may alter the metabolic profile of malignant T cells
The results suggest that Idh1 has a physiological function in protecting cells from oxidative stress by regulating the intracellular NADP(+)/NADPH ratio.
These results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1 mutations R132H.
MiR (zeige MLXIP ELISA Kits)-181a regulates lipid metabolism via IDH1
revealed a role for IDH1 in the synthesis/turnover of phospholipids in developing astrocytes and highlight the lipid alterations resulting from the loss of wild-type IDH1 activity.
these data show that mutant IDH or d-2HG causes persistence of chondrocytes, giving rise to rests of growth-plate cells that persist in the bone as enchondromas.
Data suggest that the expression of cytosolic NADP+-dependent isocitrate dehydrogenase in bovine mammary epithelium is modulated by regulators of differentiation including extracellular matrix and lactogenic hormones as well as metabolic effectors.
Tyr140 and Lys212 are required for the catalytic activity of porcine NADP-dependent isocitrate dehydrogenase (zeige IDH3B ELISA Kits)
analysis of the coenzyme binding site in the porcine mitochondrial NADP-dependent isocitrate dehydrogenase (zeige IDH3B ELISA Kits)
These results suggest that IDPm (zeige IDH2 ELISA Kits) plays an important protective role in cadmium-induced apoptosis by maintaining cellular redox status and by protection of Grx (zeige GRX1 ELISA Kits) activity.
Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.
isocitrate dehydrogenase 1 (NADP+), soluble
, isocitrate dehydrogenase [NADP] cytoplasmic-like
, NADP(+)-specific ICDH
, NADP-dependent isocitrate dehydrogenase, cytosolic
, NADP-dependent isocitrate dehydrogenase, peroxisomal
, isocitrate dehydrogenase [NADP] cytoplasmic
, oxalosuccinate decarboxylase
, cytosolic NADP-isocitrate dehydrogenase
, isocitrate dehydrogenase 1
, Isocitrate dehydrogenase 1, soluble
, NADPH-specific isocitrate dehydrogenase
, isocitrate dehydrogenase [NADP], mitochondrial